



PRESS RELEASE

## **Foamix and Intendis Sign License Agreement for the Development of a dermatological Foam**

**Berlin, Germany and Ness Ziona, Israel, January 10, 2007**

Intendis GmbH and Foamix Ltd., the leader in the development of topical foam delivery systems, announced today that they have executed a worldwide license agreement for a dermatological foam. The agreement was signed following successful completion of Foamix's development of a novel alcohol-free foam.

Under the terms of the agreement, Intendis is to pay Foamix a signing fee and milestone payments, as well as royalties based on net sales.

"We are pleased to announce this license agreement with Foamix. Foamix has a proven track record of developing innovative dermatological foams and we are confident that this product will be an important addition to our range of products", said Prof. Dr. Wolfgang Kehr, President and CEO of Intendis.

"This agreement with Intendis, a leader in the field of dermatology, validates our expertise in the development of dermatological foams", said Foamix CEO, Dr. Dov Tamarkin. "We welcome the opportunity to work with such a well respected partner."

### **About Foamix**

Headquartered in Ness Ziona, Israel, Foamix Ltd. develops alcohol-free, stable foam products for prescription, OTC and cosmetic uses. Foamix's state-of-the-art foams provide controlled delivery of a variety of active ingredients. They are also able to enhance intradermal delivery of actives, for optimal effect. The company's development capabilities range from initial development of foam formulations to scale-up, GMP manufacturing, preclinical and clinical studies. Foamix is a privately held company, whose business model is based on partnering with leading pharma companies to develop products utilizing its proprietary foam technologies. Foamix holds 3 patents and has 33 patents pending.

For additional information please visit [www.foamix.co.il](http://www.foamix.co.il).

Press inquiries: Sigal Maimon, Foamix Ltd, +972 8 931 62 33, Ext. 104 or [info@foamix.co.il](mailto:info@foamix.co.il).



### **About Intendis**

Intendis is a fully integrated pharmaceutical company – dedicated to dermatology. Intendis is focused on the development, manufacturing and marketing of high quality, innovative topical and systemic therapies, targeted to treat skin disorders. The current product portfolio comprises treatments of eczema disorders including atopic dermatitis, as well as psoriasis, acne, rosacea and fungal skin infections (mycoses). Intendis markets a number of successful brands such as Advantan® and Nerisona® for the treatment of eczema, Travocort® (dermatomycoses), Skinoren® (acne), Finacea® (rosacea) and Psorcutan® and Psorcutan® Beta (psoriasis). The company's objective is to become a leading partner in the field of dermatology. Intendis GmbH is a wholly owned subsidiary of Bayer Schering Pharma AG, Germany.

For additional information please visit [www.intendis.com](http://www.intendis.com).

Press inquiries: Sven Winkler, Intendis GmbH, +49 30 52 00 75 650 or  
[media@intendis.com](mailto:media@intendis.com)

Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and Intendis' plans and objectives to differ materially from those expressed or implied in the forward-looking statements. Intendis GmbH undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.